A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Fibrosis

In brief

The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.

Key facts

Study ID

NCT04308681

Run by

Bristol-Myers Squibb

People needed

403

Starts

2020-07-29

Expected to finish

2023-09-22

Last updated by the study team

2026-02-03

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• For the idiopathic pulmonary fibrosis (IPF) Cohort
• Diagnosis of IPF within 7 years of screening
• Female and males ≥ 40 years of age
• For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort
• Evidence of progressive ILD within the 24 months before screening
• Female and male ≥ 21 years of age.

You may not qualify if…

• Women of childbearing potential (WOCBP)
• Active Smokers
• Current malignancy or previous malignancy up to 5 years prior to screening
• History of allergy to BMS-986278 or related compounds
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution — Phoenix, Arizona, United States
• Local Institution - 0028 — Los Angeles, California, United States
• Local Institution - 0043 — Stanford, California, United States
• University of Colorado Anschutz Medical Campus-Department of Medicine — Aurora, Colorado, United States
• Local Institution - 0006 — Denver, Colorado, United States
• Local Institution - 0171 — New Haven, Connecticut, United States
• Local Institution - 0035 — Gainesville, Florida, United States
• Local Institution - 0166 — Orlando, Florida, United States
• Local Institution - 0078 — Atlanta, Georgia, United States
• Local Institution - 0031 — Kansas City, Kansas, United States
• Local Institution - 0154 — Baltimore, Maryland, United States
• Local Institution - 0003 — Boston, Massachusetts, United States
• Local Institution - 0030 — Chesterfield, Missouri, United States
• Local Institution - 0036 — St Louis, Missouri, United States
• Local Institution - 0029 — Cincinnati, Ohio, United States
• Local Institution - 0164 — Columbus, Ohio, United States
• Local Institution — Hershey, Pennsylvania, United States
• Local Institution — Nashville, Tennessee, United States
• Local Institution - 0096 — Charlottesville, Virginia, United States
• Local Institution — Falls Church, Virginia, United States
• Local Institution - 0049 — Buenos Aires, Distrito Federal, Argentina
• Local Institution - 0103 — Rosario, Santa Fe Province, Argentina
• Local Institution - 0097 — San Miguel de Tucumán, Tucumán Province, Argentina
• Local Institution - 0115 — Buenos Aires, Argentina
• Local Institution - 0032 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.